hMAM mRNA在检测乳腺癌外周血微小转移中的应用

Mammaglobin mRNA measurement in the detection of micrometastasis in peripheral blood of breast cancer patients

目的 探讨乳腺组织特异性基因hMAMmRNA作为检测乳腺癌血道微小转移指标的可能性。方法 采用巢式PCR结合荧光定量PCR ,对 6 3例乳腺癌患者、8例乳腺增生患者、5例乳腺纤维腺瘤患者、2 5例其他癌患者以及 31例健康志愿者的外周血进行检测。结果 6 3例乳腺癌患者外周血中hMAMmRNA阳性率 30 .2 % (19/6 3) ,手术后阴转率为 31.6 % (6 /19)。乳腺良性疾病、胃癌、大肠癌、食管癌、肺癌、卵巢癌患者外周血中均阴性 ,而 31例健康献血员中有 1例阳性。hMAMmRNA表达随肿瘤分期进展阳性率增高 ,但与肿瘤分期、ER和PR状态无关 (P >0 .0 5 )。结论 hMAMmRNA特异表达于乳腺癌患者外周血 ,有可能作为检测乳腺癌血道微小转移的指标。

Objective To investigate mammanglobin (hMAM) mRNA as a marker for the detection of carcinoma cells by reverse transcriptase chain reaction (RT PCR) in the peripheral blood of breast cancer patients.Methods Blood samples from 63 breast cancer patients obtained at various stages of their disease, blood samples from 8 breast hyperplasia, 5 breast adenofibroma, 25 other cancers (stomach, colon, esophagus, lung, ovary) and 31 healthy volunteers were screened for hMAM mRNA by a nested RT PCR combined with fluorescence quantitative PCR (FQ PCR) assay. Results Among 63 breast carcinoma patients, 19(30.2%) were RT PCR positive for hMAM mRNA which was elevated with the tumor stage. None of the other cancer patients or those suffering from benign breast diseases were positive but only 1 of the 31 healthy volunteers gave detectable hMAM mRNA findings. hMAM mRNA was not detectable in the peripheral blood after operation in 6(32%) of 19 patients whose pre operative test had been positive even though the hMAM mRNA expression increased with tumor stage. These results did not correlate with patients′ stage, estrogen or pregnant receptor status. Conclusion hMAM transcripts are detectable in the peripheral blood of some breast cancer patients. hMAM may be a novel candidate and a clinically useful breast tumor marker, especially in detecting micrometastasis.